The Possible Positive Mechanisms of Pirenoxine in Cataract Formation.

Tytuł:: The Possible Positive Mechanisms of Pirenoxine in Cataract Formation.
Autorzy:: Upaphong P; Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.; Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Thonusin C; Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, Thailand.
Choovuthayakorn J; Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Chattipakorn N; Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, Thailand.
Chattipakorn SC; Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai 50200, Thailand.; Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Chiang Mai 50200, Thailand.
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2022 Aug 21; Vol. 23 (16). Date of Electronic Publication: 2022 Aug 21.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:: Cataract*/drug therapy
Cataract*/etiology
Cataract*/prevention & control
Lens, Crystalline*
Antioxidants/pharmacology ; Antioxidants/therapeutic use ; Humans ; Oxazines/pharmacology
References:: J Photochem Photobiol B. 2003 Oct 15;71(1-3):59-68. (PMID: 14705640)
Inorg Chem. 2011 Jan 3;50(1):365-77. (PMID: 21138325)
Eye (Lond). 2019 Nov;33(11):1823-1825. (PMID: 31554952)
Sci Rep. 2017 Jul 28;7(1):6819. (PMID: 28754903)
Eur Rev Med Pharmacol Sci. 2021 Jul;25(13):4520-4526. (PMID: 34286494)
Indian J Ophthalmol. 1980 Apr;28(1):1-3. (PMID: 7203589)
Indian J Ophthalmol. 1981 Oct;29(3):147-9. (PMID: 7346417)
Exp Eye Res. 1975 Feb;20(2):180. (PMID: 235444)
Evid Based Complement Alternat Med. 2012;2012:426537. (PMID: 23365598)
Bosn J Basic Med Sci. 2010 Aug;10(3):265-9. (PMID: 20846136)
Exp Eye Res. 2010 Jun;90(6):664-78. (PMID: 20230820)
J Ethnopharmacol. 2015 Aug 22;172:238-46. (PMID: 26119284)
Int J Biol Macromol. 2016 Oct;91:895-904. (PMID: 27316765)
Pharmaceuticals (Basel). 2020 Jan 16;13(1):. (PMID: 31963166)
Ophthalmic Res. 1999;31(2):140-2. (PMID: 9933777)
Vojnosanit Pregl. 2009 May;66(5):371-5. (PMID: 19489472)
Indian J Ophthalmol. 2014 Feb;62(2):103-10. (PMID: 24618482)
Lancet Glob Health. 2021 Apr;9(4):e489-e551. (PMID: 33607016)
BMC Health Serv Res. 2006 Jul 27;6:92. (PMID: 16872522)
Free Radic Res. 2016 Oct;50(10):1116-1130. (PMID: 27383194)
Exp Eye Res. 2005 May;80(5):709-25. (PMID: 15862178)
J Photochem Photobiol B. 2005 Jan 14;78(1):35-42. (PMID: 15629247)
Biochem Int. 1990;20(6):1097-103. (PMID: 2369412)
Med Sci Monit. 2005 Sep;11(9):RA301-10. (PMID: 16127377)
Vestn Oftalmol. 2010 Jan-Feb;126(1):36-9. (PMID: 20645574)
Protein Pept Lett. 2017;24(11):1048-1058. (PMID: 28782478)
Contact Dermatitis. 2004 Jun;50(6):375-6. (PMID: 15274732)
Biomed Environ Sci. 1997 Sep;10(2-3):333-9. (PMID: 9315327)
Ocul Surf. 2009 Oct;7(4):176-85. (PMID: 19948101)
Indian J Ophthalmol. 1983 Jan;31(1):5-8. (PMID: 6354928)
Indian J Ophthalmol. 1978 Apr;26(1):6-8. (PMID: 711283)
Pharmacol Res. 1995 May;31(5):325-9. (PMID: 7479531)
Clin Exp Optom. 2010 Nov;93(6):379-89. (PMID: 20735786)
Int J Ophthalmol. 2016 Oct 18;9(10):1506-1517. (PMID: 27803872)
Aging Cell. 2017 Apr;16(2):244-261. (PMID: 28177569)
Mol Vis. 2010 Mar 16;16:445-53. (PMID: 20300567)
Dev Ophthalmol. 2005;38:89-102. (PMID: 15604619)
Biol Trace Elem Res. 2011 Jul;142(1):106-16. (PMID: 20596791)
Curr Opin Ophthalmol. 2017 Jan;28(1):98-103. (PMID: 27820750)
Exp Eye Res. 1999 Mar;68(3):347-59. (PMID: 10079143)
Z Naturforsch C J Biosci. 1991 Mar-Apr;46(3-4):280-4. (PMID: 1878111)
Ophthalmologica. 2000 Sep-Oct;214(5):332-6. (PMID: 10965246)
Ageing Res Rev. 2002 Jun;1(3):465-79. (PMID: 12067598)
Klin Oczna. 2004;106(6):778-82. (PMID: 15787181)
Amino Acids. 1991 Jun;1(2):263-78. (PMID: 24194112)
Adv Drug Deliv Rev. 2018 Feb 15;126:185-194. (PMID: 29604375)
J Ocul Pharmacol. 1987 Fall;3(3):211-25. (PMID: 3332678)
Front Physiol. 2019 Jun 04;10:688. (PMID: 31231240)
Lancet Glob Health. 2021 Feb;9(2):e144-e160. (PMID: 33275949)
J Toxicol Clin Toxicol. 2000;38(2):123-8. (PMID: 10778908)
Open Ophthalmol J. 2017 Oct 31;11:305-314. (PMID: 29299077)
Case Rep Ophthalmol. 2012 May;3(2):262-5. (PMID: 22949915)
J Ophthalmol. 2010;2010:608751. (PMID: 20634936)
Prog Biophys Mol Biol. 2004 Nov;86(3):407-85. (PMID: 15302206)
Mol Vis. 2011;17:1862-70. (PMID: 21850160)
Grant Information:: Senior Research Scholar Grant (SCC) National Research Council of Thailand; CMU Excellent Center Award (NC) Chiang Mai University; NSTDA Research Chair Grant (NC) National Science and Technology Development Agency
Contributed Indexing:: Keywords: Catalin; Kary uni; PRX; anticataract; antioxidant; eye
Substance Nomenclature:: 0 (Antioxidants)
0 (Oxazines)
27L0EP6IZK (pirenoxine)
Entry Date(s):: Date Created: 20220826 Date Completed: 20220829 Latest Revision: 20220830
Update Code:: 20240105
PubMed Central ID:: PMC9408903
DOI:: 10.3390/ijms23169431
PMID:: 36012695
: Czasopismo naukowe

Pełny tekst

Cataract is the leading cause of blindness worldwide. A diverse range of medication has been invented to prevent or treat cataract. Pirenoxine (PRX), a drug with strong antioxidant properties, has been used topically to treat cataract, and there is much evidence to demonstrate the beneficial effects of PRX on lens opacity from in vitro and in vivo models. In clinical use, PRX has been prescribed worldwide by ophthalmologists for over six decades; however, there is still controversy with regard to its efficacy, and thus PRX remains an off-label use for cataract treatment. This comprehensive review summarizes and discusses evidence pertinent to the mechanisms of PRX and its efficacy mainly on cataract models. The issues that have been deemed uncertain over the six-decade use of PRX are examined. The information summarized in this review should provide insights into contriving novel approaches for the treatment of cataract.
Competing Interests: The authors declare no conflict of interest.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja